Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiDoxyR-PEP study of doxycycline post-exposure prophylaxis, bacterial resistance, and gut microbiota
2025-525150-19-01Phase 4Authorised
- Sponsor
- IDIVAL
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of doxycycline in sexually transmitted disease (STD) (2 arms), sponsored by IDIVAL. Primary endpoint: Prevalence of nasal colonization by doxycycline-resistant Staphylococcus aureus. Planned start Sep 2026; status: authorised.
02
Drugs
doxycycline
03
Conditions
sexually transmitted disease (STD)
Beyond the preview
Go deeper on 2025-525150-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525150-19-01.